Press Releases July 30, 2026 05:00 PM

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026

FocalTherics schedules Q2 2026 financial results announcement and webcast for August 13, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
FOCL

FocalTherics, a global leader in robotic focal therapy and minimally invasive medical devices, will release its second quarter 2026 financial results after market close on August 13, 2026. The company will host a conference call and webcast featuring senior management to discuss the results.

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
FOCL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FocalTherics is releasing Q2 2026 financial results on August 13, 2026.
  • The company specializes in robotic focal therapy using focused ultrasound technology.
  • A conference call and webcast will allow investors and analysts to engage with management about the quarterly performance.

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026

Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT

AUSTIN, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced that it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. 

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, August 13, 2026, at 4:30 p.m. Eastern TimeDomestic: 1-800-245-3047International: 1-203-518-9765Passcode: FOCAL Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767672&tp_key=2d69d92ca7

About FocalTherics
A recognized global leader in Robotic Focal Therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life. FocalTherics is committed to expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and global market development initiatives. For more information about FocalTherics, visit FocalTherics.com.

Investor Contacts
Louisa Smith
Gilmartin Group
investor.relations@focalone.com


Risks

  • Financial results may reflect uncertainties or challenges not detailed in the release, impacting stock performance.
  • The adoption and market expansion of novel robotic focal therapy technology may face competitive or regulatory risks.
  • Clinical outcomes and physician adoption rates could affect revenue growth and market position.

More from Press Releases

VEON and Beeline Kazakhstan Sign Payments Cooperation Memorandum with National Bank of Kazakhstan Sep 15, 2026 BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer Sep 15, 2026 Bread Financial Provides Performance Update for August 2026 Sep 15, 2026 Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™ Sep 15, 2026 Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD Sep 15, 2026